Zelnecirnon
- Generic Name
- Zelnecirnon
Phase 2 Study to Evaluate RPT193 in Adults With Moderate to Severe T2-high Asthma
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 38
- Registration Number
- NCT05935332
- Locations
- 🇺🇸
Coral Research Clinical Corp, Miami, Florida, United States
🇵🇱NZOZ Poradnie Specjalistyczne Atopia, Kraków, Poland
🇵🇱Specjalistyczna Przychodnia Lekarska Alergo-Med sp. z o.o, Poznań, Poland
An Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 229
- Registration Number
- NCT05399368
- Locations
- 🇺🇸
Indiana Clinical and Translational Sciences Institute (CTSI) Clinical Research Center, Indianapolis, Indiana, United States
🇺🇸Wallace Medical Group, Los Angeles, California, United States
🇺🇸Clinical Science Institute, Santa Monica, California, United States
A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis
- First Posted Date
- 2020-02-17
- Last Posted Date
- 2021-09-30
- Lead Sponsor
- RAPT Therapeutics, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT04271514
- Locations
- 🇺🇸
Lenus Research & Medical Group, Miami, Florida, United States
🇺🇸Clinical Trials Management,LLC, Metairie, Louisiana, United States
🇳🇱PRA, Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath